Cartography Biosciences secures $67M Series B to advance precision cancer immunotherapies—Excedr covers this major biotech funding round.
Leasing lab equipment helps biotech labs stay flexible—cutting upfront costs, reducing downtime, and keeping research aligned with shifting milestones.
See how equipment leasing helps biotech startups hit milestones faster by preserving cash flow, cutting upfront costs, and accelerating R&D timelines.
Excedr covers Predicta Biosciences’ $23.4M raise to advance liquid biopsy diagnostics for multiple myeloma, replacing painful bone marrow biopsies with blood-based testing.
Axon Therapies pioneers a breakthrough in heart failure treatment with splanchnic nerve ablation—Excedr covers this major biotech funding round.
Star Therapeutics advances antibody therapies for rare blood disorders—Excedr covers this major biotech funding round.
Avenzo Therapeutics raises $60M Series B to advance next-gen cancer therapies—Excedr covers this major biotech funding round announcement.
See what investors look for in lab equipment leasing strategies—and how biotech startups can signal discipline, flexibility, and milestone focus.
Discover why biotech startups choose equipment leasing over buying—preserving cash flow, staying flexible, and aligning lab strategy with milestones.
How do preclinical biotech startups scale faster with equipment leasing? By preserving cash, reducing upfront costs, allowing them to hit milestones sooner.
